IRS Annual Fee Rule For Brand Drug Manufacturers Clarifies Orphan Drug Exclusion, Part B Calculations
This article was originally published in The Pink Sheet Daily
Policies outlined in the temporary rule will remain "applicable" until at least Aug. 15, 2014.
You may also be interested in...
Bayer and Novartis are among a number of companies pushing to ensure a broad interpretation of exemption for orphan drugs from the annual market-based fees that drug firms newly owe under the Affordable Care Act.
The biopharmaceutical industry is pushing for greater transparency around the data used by the federal government to generate preliminary estimates of the market-based fees owed to the government by individual manufacturers and importers in 2011.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.